Skip to content
  • About Impel
    • Impel History
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Collaborations
  • Migraine
  • Our Science
    • POD Technology
    • Publications & Presentations
    • Meetings
    • Clinical Trials
    • Intellectual Property
  • Join Impel
  • Investors
  • Contact
  • About Impel
    • Impel History
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Collaborations
  • Migraine
  • Our Science
    • POD Technology
    • Publications & Presentations
    • Meetings
    • Clinical Trials
    • Intellectual Property
  • Join Impel
  • Investors
  • Contact
Icon Right Caret return to previous page
back to Presentations

Impel NeuroPharma, Inc. SPECT Imaging of Direct Nose-to-Brain Transfer of MAG-3 in Man

posted in Presentations by impelstage

Presented at AAPS 2013. Poster PDF

CONNECT WITH US
Icon Twitter link to Twitter Icon LinkedIn link to linkedIn
Impel Pharmaceuticals Inc. is a Seattle-based, commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for disorders with high unmet medical needs.

IMPEL, POD, Trudhesa, Trudhesa DIRECT, and the Impel and Trudhesa Logos are trademarks of Impel Pharmaceuticals, Inc. Other trademarks are the property of the respective owner(s).

Impel Pharmaceuticals

201 Elliott Avenue West, Suite 260
Seattle, WA 98119

Phone: 206.568.1466

Privacy Policy

Terms of Service

Social Media Policy

CA Disclosure

© 2023 Impel Pharmaceuticals Inc. All Rights Reserved.

Privacy Policy

Terms of Service

Social Media Policy

CA Disclosure